Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from William Blair

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating restated by equities researchers at William Blair in a research report issued to clients and investors on Friday, September 20th, AnalystRatings.com reports. William Blair also issued estimates for Aclaris Therapeutics’ Q3 2019 earnings at ($0.58) EPS, Q4 2019 earnings at ($0.49) EPS, FY2019 earnings at ($2.74) EPS, FY2020 earnings at ($1.51) EPS and FY2021 earnings at ($1.37) EPS.

Several other equities analysts also recently weighed in on the company. Svb Leerink downgraded Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, June 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $5.00 price target (down previously from $24.00) on shares of Aclaris Therapeutics in a report on Friday, August 9th. ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. JMP Securities cut Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, September 6th. Finally, Leerink Swann cut Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 27th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $13.38.

Shares of ACRS traded up $0.23 during mid-day trading on Friday, reaching $1.42. The company had a trading volume of 4,980,300 shares, compared to its average volume of 3,197,791. The stock has a market capitalization of $47.99 million, a P/E ratio of -0.35 and a beta of 0.83. The stock has a 50 day moving average of $1.14 and a two-hundred day moving average of $3.38. The company has a quick ratio of 3.22, a current ratio of 3.23 and a debt-to-equity ratio of 0.22. Aclaris Therapeutics has a 52-week low of $0.74 and a 52-week high of $13.73.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.05. The company had revenue of $5.87 million for the quarter, compared to the consensus estimate of $5.77 million. Aclaris Therapeutics had a negative return on equity of 81.40% and a negative net margin of 979.65%. On average, sell-side analysts expect that Aclaris Therapeutics will post -2.58 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Man Group plc lifted its holdings in Aclaris Therapeutics by 73.6% during the 2nd quarter. Man Group plc now owns 2,057,936 shares of the biotechnology company’s stock worth $4,507,000 after buying an additional 872,408 shares during the last quarter. Rock Springs Capital Management LP lifted its holdings in Aclaris Therapeutics by 19.3% during the 2nd quarter. Rock Springs Capital Management LP now owns 2,028,000 shares of the biotechnology company’s stock worth $4,441,000 after buying an additional 328,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Aclaris Therapeutics by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,867,838 shares of the biotechnology company’s stock worth $4,090,000 after buying an additional 30,191 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Aclaris Therapeutics by 63.7% during the 2nd quarter. Renaissance Technologies LLC now owns 699,580 shares of the biotechnology company’s stock worth $1,532,000 after buying an additional 272,200 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Aclaris Therapeutics by 66.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 408,262 shares of the biotechnology company’s stock worth $870,000 after buying an additional 162,458 shares during the last quarter. 86.10% of the stock is owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Featured Article: Earnings Reports

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.